Metraipolis › archive › dc_89272aa2ec65
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib — Europe PMC PMID:42422880
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42422880
- DOI
- 10.3389/fmolb.2026.1878152
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T04:14:30.350Z
- SHA-256 of the archived text
393eff33791c5d2c27168a74462a4566ba13d5c861c050455c09f86f5f0c2687- Stable URL of this page
https://metraipolis.com/documento/dc_89272aa2ec65
How to cite
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib — Europe PMC PMID:42422880 — Europe PMC (en), https://europepmc.org/article/MED/42422880 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_89272aa2ec65 (Metraipolis archive dc_89272aa2ec65, sha256 393eff33791c5d2c27168a74462a4566ba13d5c861c050455c09f86f5f0c2687)
BibTeX
@misc{dc89272aa2ec65,
title = {Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib — Europe PMC PMID:42422880},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42422880},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_89272aa2ec65; sha256 393eff33791c5d2c27168a74462a4566ba13d5c861c050455c09f86f5f0c2687},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42422880. Agents can read the archived copy with the MCP tool read_document.